Abstract Triple-negative breast cancer accounts for less than 20% of breast cancers overall, but is the predominant subtype among carriers of mutations in BRCA1. However, few studies have assessed the association between breast cancer family history and risk of triple-negative breast cancer. We examined the relationship between having a family history of breast cancer in first-degree relatives and risk of triple-negative breast cancer, and risk of two other breast cancer subtypes defined by tumor marker expression. We evaluated data collected by the Breast Cancer Surveillance Consortium from 2,599,946 mammograms on 1,054,466 women, among whom 15% reported a first-degree family history of breast cancer. Using Cox regression in this cohort, we evaluated subtype-specific associations between family history and risk of triple-negative (N = 705), estrogen receptor-positive (ER?, N = 10,026), and hormone receptor-negative/HER2-expressing (ER-/PR-/HER2?, N = 308) breast cancer among women aged 40-84 years. First-degree family history was similarly and significantly associated with an increased risk of all the subtypes [hazard ratio (HR) = 1.73, 95% confidence interval (CI): 1.43-2.09, HR = 1.62, 95% CI: 1.54-1.70, and HR = 1.56, 95% CI: 1.15-2.13, for triple-negative, ER?, and ER-/PR-/ HER2?, respectively]. Risk of all the subtypes was most pronounced among women with at least two affected firstdegree relatives (versus women with no affected first-degree relatives, HR triple-negative = 2.66, 95% CI: 1.66-4.27, HR ER? = 2.05, 95% CI: 1.79-2.36, HR ER -/PR -/HER2? = 2.25, 95% CI: 0.99-5.08). Having a first-degree family history of breast cancer was associated with an increased risk of triple-negative breast cancer with a magnitude of association similar to that for the predominant ER? subtype and ER-/ PR-/HER2? breast cancer. 
Introduction
Mounting evidence indicates that breast cancer is a clinically, biologically, and epidemiologically heterogeneous disease. One subtype of breast cancer that has emerged as being of particular interest in this regard is triple-negative breast cancer. Breast cancers of the triple-negative subtype are characterized by a lack of expression of the estrogen receptor (ER), progesterone receptor (PR), and HER2, and typically exhibit a basal-like pattern of gene expression [1] . Compared to ER-positive (ER?) breast cancers, triple-negative tumors are associated with a poorer survival and more aggressive pathology [2] [3] [4] [5] . Although few risk factors for this breast cancer subtype have been identified, a number of studies have reported that triple-negative breast cancer is the predominant subtype among women carrying a deleterious germ-line mutation in BRCA1: approximately 57-80% of BRCA1-associated breast cancers exhibit the triple-negative phenotype, compared to less than 20% of sporadic breast cancers [6, 7] . However, the extent to which the association between BRCA1 and the triple-negative subtype translates to breast cancer subtype-specific differences in the association with family history of breast cancer has not been well studied.
Given that triple-negative subtype accounts for less than 20% of invasive breast cancers [8, 9] , and given the relatively recent advent of widespread testing for HER2 expression, few large population-based studies have been able to assess the association between a woman's family history and risk of developing triple-negative breast cancer. Two prior studies evaluated the association between family history and risk of basal-like breast cancer (i.e., triple-negative and positive for EGFR and/or cytokeratin 5/6 expression) [10, 11] : one study found no difference in the prevalence of family history among women with basal-like breast cancer as compared to women with ER? and/or HER2-expressing breast cancers [11] , while the other reported an increased breast cancer risk among women with a breast cancer family history that was the greatest in magnitude for basal-like breast cancer [10] . In the context of such limited and inconsistent data, the relationship between breast cancer family history and triplenegative breast cancer risk remains unclear.
Using data from the Breast Cancer Surveillance Consortium (BCSC), we assessed the association between family history of breast cancer in first-degree relatives and risk of three breast cancer subtypes defined by ER, PR, and HER2 status among women aged 40-84 years undergoing breast cancer screening.
Materials and methods
The BCSC is a collaborative effort between seven geographically dispersed mammography registries, the details of which have been provided elsewhere [12] . The present analysis includes data from six BCSC registries that collected data on ER, PR, and HER2 status. All BCSC registries collect risk factor information through selfadministered questionnaires completed by women at the time of screening mammography (http://breastscreening. cancer.gov/data/elements.html), including data on attained age, race, Hispanic ethnicity, history of prior breast procedures, and history of breast cancer in first-degree relatives. Women are asked to self-report separately whether breast cancer has previously been diagnosed in: (1) their mother, (2) any sisters, and/or (3) any daughters. Since women may have multiple affected sisters and/or daughters, some BCSC registries also collect information on the number of affected sisters and daughters. All the registries collect some information regarding the age at breast cancer diagnosis of first-degree relatives.
Each registry and the BCSC Statistical Coordinating Center have received institutional review board approval for either active or passive consenting processes or a waiver of consent to enroll participants, link data, and perform analytic studies. All the procedures are Health Insurance Portability and Accountability Act compliant, and all the registries and the Statistical Coordinating Center have received a Federal Certificate of Confidentiality and other protection for the identities of women, physicians, and facilities who are subjects of this research.
Study population
We included women aged 40-84 years with no prior history of invasive or in situ breast cancer at the time of mammography screening. Women meeting these criteria who received at least one screening mammogram (http:// breastscreening.cancer.gov/data/bcsc_data_definitions.pdf) at a BCSC-associated facility during the study period were included. The timing and duration of the study period varied between registries, reflecting differences in the earliest breast cancer diagnosis date for which HER2 data were available and the date up to which cancer ascertainment was complete. Registry-specific study period start dates ranged from January 1, 1999 to January 1, 2003; registry-specific study period end dates ranged from May 31, 2007 to October 31, 2008.
After excluding women not meeting eligibility criteria, 2,599,946 mammograms from 1,054,466 women were eligible for inclusion in the present analysis. The average duration of follow-up contributed by women was 3.7 years (range 0-9.0 years) from the time of the first eligible screening mammogram in the study period until either the end of the study period or breast cancer diagnosis, whichever came first. Among the 629,973 women (60%) who received more than one mammogram during the study period, the average time between examinations was 1.5 years (range 0.7-8.9 years).
Case population
Breast cancers were identified by each BCSC registry through linkage with cancer registries and/or pathology databases. Data on tumor characteristics were also obtained through linkage with these resources. Study cases included women diagnosed with an invasive breast cancer subsequent to a screening mammogram within the study period. The median time between breast cancer diagnosis and a case's most recent prior screening mammogram was 56 days (range 0 days to 8.3 years). Women diagnosed with invasive breast cancer on the same day as their first screening mammogram during the study period (N = 431) were recoded such that they contributed 1 day of follow-up and could thus contribute to the analysis. Women diagnosed with in situ breast cancer during the study period (N = 3,689) were not considered as cases and were censored at the time of in situ diagnosis.
Cases with a HER2 result of 0, 1?, or 2? on immunohistochemistry (IHC) testing and/or a negative or borderline result on fluorescence in situ hybridization (FISH) testing were considered HER2-negative; conversely, cases with positive FISH and/or a HER2 result of 3? on IHC were considered HER2-expressing. Among 13,797 women diagnosed with invasive breast cancer during the study period, 10,026 were identified as ER? (regardless of PR and HER2 status), 308 were identified as hormone receptor-negative HER2-expressing (i.e., ER-/PR-/HER2?), and 705 were identified as triple-negative (i.e., ER-, PR-, HER2-). An additional 2,585 cases could not be classified into a subtype due to insufficient tumor marker data (1,562 missing ER status and 1,023 ER-/PR-with missing HER2 status), and 173 were ER-and either PR? or missing PR status; these cases were censored from all the analyses at the time of diagnosis.
Statistical analyses
We used Cox proportional hazards regression to evaluate the association between history of breast cancer in first-degree relatives and breast cancer risk. Given our interest in assessing risk factor associations separately for different subtypes of breast cancer, we constructed separate regression models specific to each of three breast cancer subtypes of interest (i.e., ER?, ER-/PR-/HER2?, and triple-negative). In all the models, the time axis was defined as the time (in days) since a woman's first eligible screening mammogram during the study period, and women diagnosed with invasive breast cancer of a subtype other than the modelspecific outcome were censored at the time of diagnosis.
Analyses were adjusted for a limited set of confounders that altered coefficient estimates by at least 10%, including age at the start follow-up (5-year categories), race (white/ non-white), and prior history of a benign breast procedure (yes/no). We analyzed the primary exposure of interest, history of breast cancer in first-degree relatives, as a dichotomous variable (yes/no). Exposure variables and covariates other than age were analyzed as time-varying to allow for changes in variable values with mammograms subsequent to the first qualifying mammogram. We evaluated proportional hazards assumptions by testing for a non-zero slope of the scaled Schoenfeld residuals on ranked failure times and on the log of analysis time. Analyses were conducted using STATA SE version 10.1 (College Station, Texas).
In light of previous reports indicating that family history is most strongly associated with breast cancer risk in young women [13, 14] , we evaluated subtype-specific hazard ratios both overall and within two broad age strata (age 40-54/55-84 years). In separate analyses, we examined how subtype-specific associations with family history differed according to the number of affected first-degree relatives and according to the age at which affected relatives were diagnosed with breast cancer. Since two BCSC registries ascertain only whether the participant has an affected sister and/or daughter but not the number of affected sisters or daughters, there were instances where we could not determine whether women reporting a family history had only one or more than one affected first-degree relative. To accommodate this issue, we analyzed the number of affected first-degree relatives as a three-level categorical term: no family history, one or more affected relatives, and two or more affected relatives. Although the latter two of these categories overlap, categories were coded to be mutually exclusive; that is, women were included in the middle category only if they reported having one affected relative or if it was not possible to distinguish whether they had only one or more than one affected relatives. The age at breast cancer diagnosis of first-degree relatives was also analyzed as a categorical variable (no family history/family history with no relatives diagnosed before age 50/family history with one or more relatives diagnosed before age 50). We also compared hazard ratio (HR) estimates across case groups using competing risks partial likelihood methods [15] .
Family history variables and most covariates in the regression models were associated with some missingness. Since the exposures and covariates considered here were unlikely to change with great frequency over follow-up, a filling process was used to resolve missing values: missing values of a variable were replaced with non-missing data from the same woman provided at a prior mammogram or, if no prior non-missing data were available, with non-missing data provided at a subsequent mammogram from the same woman. In sensitivity analyses, we also used multiple imputation methods [16] to assess the impact of missingness in exposures and covariates remaining after filling and the impact of missingness in tumor marker data. Specifically, we constructed an imputation model that included all the exposures and covariates, an observationlevel categorical outcome indicator variable, the log of analysis time, and tumor characteristics, and applied this imputation model to all the analyses.
Results
The distributions of demographic characteristics and covariate variables in the overall study population are presented in Table 1 . The majority of the study population was non-Hispanic white (74%) and had education beyond high school (66%). Differences were noted across case groups in the distribution of age at most recent screening mammogram, histologic subtype, and stage and grade at diagnosis ( Table 2 ). In particular, ER? breast cancers were more likely to be diagnosed as stage I disease (60% vs. 40% and 44% in ER-/PR-/HER2? and triple-negative cases, respectively) and less likely to be classified as high grade (20% in grades 3 and 4 vs. 65% and 72% of ER-/PR-/ HER2? and triple-negative cases, respectively).
Women who reported having a family history of breast cancer in first-degree relatives experienced an increased risk of breast cancer that was statistically significant and similar in magnitude with respect to ER? [HR = 1.62, 95% confidence interval (CI): 1.54-1.70], ER-/PR-/HER2? (HR = 1.56, 95% CI: 1.15-2.13), and triple-negative (HR = 1.73, 95% CI: 1.43-2.09) subtypes (Table 3) . Differences between subtypes were more apparent when analyses were stratified by attained age. HR's characterizing the association between family history and risk of triple-negative breast cancer were almost identical among women aged \55 years (HR = 1.72, 95% CI: 1.27-2.33) and women aged C55 (HR = 1.74, 95% CI: 1.36-2.22). For ER? breast cancer, family history was more strongly associated with risk among younger women (HR \55 = 1.80, 95% CI: 1.66-1.95; HR C55 = 1.52, 95% CI: 1.42-1.62; P-value for interaction \ 0.01). The opposite was true for ER-/PR-/HER2? breast cancer: although CIs were wide and overlapping, family history was more strongly associated with risk among women aged C55 (HR \55 = 1.27, 95% CI: 0.80-2.01; HR C55 = 1.89, 95% CI: 1.24-2.87, P for interaction = 0.26). Overall and within each age strata there was no statistical evidence of significant differences between HR estimates for the three tumor subtypes (P-value for homogeneity = 0.77, 0.32, and 0.38, in women overall, age \55, and age C55, respectively).
Across subtypes, the increased breast cancer risk associated with family history was strongest among women who reported having at least two affected first-degree female relatives (compared to women with no family history: HR ER? = 2.05, 95% CI: 1.79-2.36; HR ER-/PR-/ HER2? = 2.25, 95% CI: 0.99-5.08; HR triple-negative = 2.66, 95% CI: 1.66-4.27) ( Table 4) . Although based on small numbers, and although subtype-specific CI's overlapped, the association between having multiple affected firstdegree relatives and breast cancer risk was especially pronounced for the triple-negative subtype. Analyses distinguishing women with a breast cancer family history according to whether any relatives were diagnosed before age 50 did not reveal any significant differences within subtypes. Analysis of partial likelihoods indicated that any observed differences in HR's across subtypes were not statistically significant [P-value (number of affected relatives) = 0.87; P-value (age of affected relatives) = 0.85]. 
Discussion
The results of these analyses are consistent with prior studies in indicating that having a history of breast cancer in first-degree relatives is associated with significantly increased breast cancer risk, especially for women with multiple affected first-degree relatives [13, 14, 17, and 18 ].
Here we find that this increased risk is of similar magnitude Certain limitations should be considered when interpreting the results presented here. HER2 status was unknown for 48% of ER-/PR-cases. Excluding these cases from the triple-negative and ER-/PR-/HER2? case groups could have resulted in some bias: missingness in HER2 varies across BCSC registries and, within registries, could also vary according to patient and tumor characteristics. Although BCSC registry identifiers are not available to investigators outside the Statistical Coordinating Center, we assessed the potential impact of missingness in HER2 status (and other variables) through sensitivity analyses using multiple imputations. Results from these analyses agreed with results from the primary analysis: multiply imputed HR's for the association between first-degree family history and breast cancer risk remained statistically significant and similar in magnitude across subtypes (HR ER? = 1.58, 95% CI: 1.50-1.65, HR ER-/PR-/HER2? = 1.40, 95% CI: 1.15-1.70, and HR triple-negative = 1.53, 95% CI: 1.35-1.73).
Given that this large study cohort was identified from women who had received screening mammography, these results are generalizable to women aged 40-84 years receiving breast imaging screening. As such, the observed distributions of characteristics such as first-degree family history could differ from what would be expected in the absence of such selection criteria: the average number of mammograms received by women who reported a family history was slightly greater than among women reporting no family history (2.57 vs. 2.32 mammograms, respectively). Population-based studies of postmenopausal women in the United States have reported prevalence estimates for firstdegree family history between 11 and 13% [19, 20] , which is modestly different from the 15% reported here. Additionally, while the case population included both screendetected and interval cases, the study setting could have impacted the distribution of tumor characteristics and case subtypes. The triple-negative subtype in particular may be under-represented in screening populations: given the earlier average age at diagnosis of triple-negative breast cancer [2, 7, 9, and 21] , women diagnosed with these tumors are likely to have had fewer and less regular screenings prior to diagnosis than women diagnosed with ER? breast cancer. While prior studies have suggested the triple-negative subtype accounts for 13-30% of invasive breast cancers [9, 11, and 21] , we found that 11% of cases with complete tumor marker data were triple-negative. The lower prevalence of the triple-negative subtype reported here could also reflect study demographics: the prevalence of this subtype is the highest among early onset breast cancer cases [2, 9] and African-American women [2, 9] , whereas this study was restricted to women aged 40-84, and approximately 7% of cases were African-American.
Although analyses indicated no significant differences across subtypes (both overall and stratified by age), it is Having a family history of breast cancer in first-degree relatives is one of the most consistently reported risk factors for breast cancer overall. In the largest study to date, a collaborative reanalysis of more than 58,000 breast cancer cases, women with one affected first-degree relative were found to have a 1.8-fold increased breast cancer risk, while women with two or with three or more affected relatives had a 2.9-fold and a 3.9-fold increased risk, respectively [13] . The slightly larger magnitude of associations observed in this prior study likely reflects the inclusion of a younger study population than that of the present analysis. In contrast to this earlier study and others not stratified by tumor subtype [13, 14, 18] , we found no difference in breast cancer risk according to the age at diagnosis of affected first-degree relatives. However, this too may reflect the older age range of our study population since studies that find a gradient of increasing risk with decreasing age at diagnosis of first-degree relatives typically note that this gradient is most pronounced with respect to earlier-onset breast cancer [13, 14] .
While the association between family history and overall breast cancer risk is well-established, previous studies characterizing heterogeneity in the association between family history and risk of different subtypes of breast cancer defined by tumor marker expression have been limited and inconsistent [10, 11, [23] [24] [25] [26] . A prior systematic review of the literature suggested no marked differences in associations with first-degree family history according to hormone receptor status [25] . Jointly stratifying case groups by ER, PR, and HER2 expression status within one of the BCSC registries included in this study, Welsh et al. [26] found that family history was associated with an increased risk of ER? and ER-/PR-/HER2? breast cancers but not triple-negative breast cancer; however, those findings were based on a sample size of only 53 triple-negative cases and a shorter duration of follow-up. The two studies to have used a five-marker definition for the basal-like subtype of breast cancer (i.e., triple-negative and cytokeratin 5/6-positive and/or EGFR-positive) have conflictingly reported that family history is most strongly associated with risk of basal-like breast cancer [10] and that there are no differences in associations with family history by molecular subtype [11] .
There is considerable evidence to support a predominance of the triple-negative phenotype in BRCA1-associated breast cancers [6, 7] . Therefore, there is reason to anticipate a higher prevalence of BRCA1 mutations in women with triple-negative breast cancer than in cases of other tumor types. However, the association between family history and breast cancer risk reflects much more than the contribution of BRCA1. Associations between family history and risk of each breast cancer subtype reflect the combined influence of high penetrance mutations (e.g., BRCA1, BRCA2), mutations of lower penetrance or prevalence (e.g., ATM, TP53) and susceptibility alleles conferring more moderate risks [27] , and associations with the shared environment and lifestyle factors that first-degree relatives often have in common. With the exception of what is known about the association between germ-line mutations in BRCA1 and the triple-negative subtype, the extent to which these aspects of family history differ in their distribution and role in different breast cancer subtypes remains unknown.
From clinical and biological perspectives, triple-negative breast cancer is a distinct disease. However, aside from the noted link between BRCA1-associated breast cancer and the triple-negative phenotype, few risk factors for triple-negative breast cancer have been identified. As the largest study of this relationship to date, the results presented here provide strong evidence that women with a breast cancer family history experience a significantly increased risk of triple-negative breast cancer. However, these results also suggest that the association between firstdegree family history of breast cancer and breast cancer risk is similar across subtypes of breast cancer defined on the basis of ER, PR, and HER2 expression.
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